Gradientech

Executive Summary

Gradientech is a Swedish diagnostics company that has developed QuickMIC®, an ultra-rapid antibiotic susceptibility testing (AST) system. The platform delivers precise Minimum Inhibitory Concentration (MIC) results directly from positive blood cultures within 2–4 hours, dramatically accelerating sepsis diagnosis compared to conventional 24–48 hour methods. This speed enables earlier targeted antibiotic therapy, improving patient outcomes and supporting antimicrobial stewardship. The company is based in Gothenburg and was founded in 2017. QuickMIC has obtained regulatory approval (CE marking) in Europe and is positioned to address the growing global need for rapid AST solutions amid rising antimicrobial resistance. Looking ahead, Gradientech's key catalyst is the pursuit of U.S. FDA clearance, which would open the large and lucrative American diagnostics market. The company is also likely to scale commercial operations in Europe and seek strategic partnerships with hospital groups or diagnostic distributors to drive adoption. With antimicrobial resistance being a top public health priority, Gradientech's differentiated speed-to-result gives it a competitive edge. However, as a private company with limited public financial disclosure, valuation and revenue traction remain opaque, warranting cautious conviction.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for QuickMIC system70% success
• Q1 2027Commercial launch in the United States60% success
• Q3 2026Strategic distribution partnership with a major diagnostics company50% success